Multiplmiyelom 'da umut vaat eden yeni tedavilere ulaşmak için lütfen tıklayınız.

Klinik Araştırmalar
Bilgilendirme Toplantıları
Takip edin
1.Erdogan M, Inal A, Ozgu M, Beksac MS, Ergurbuz I. Effect of oral contraceptive (ethinyl estradiol and d-norgestrel) on serum prolactin-oestradiol and progesterone levels Acta Reprod Turc. 1980 Jan;1(3):85-91.

2.Beksaç M.S., Kişnişçi H.A., Çakar A.N. and Beksaç M.: The endocrinological evaluation of bilateral and unilateral oophorectomy in premenopausal women. Int. J. of Fertility 28: 219-224, 1983.

3.Beksaç M.S., Beksaç M., Kişnişçi H.A. and Kökçü A.: Stress  induced release of cortisol and prolactin during dilatation and curettage under general and local anesthesia.  Neuropsychobiology 11: 227-228, 1984.


4.      Beksaç M., Porwit Ksiazek A., Hast R., Biberfeld P. and Reizenstein P.: Cytotoxicity of monoclonal antibodies against individually immunophenotyped human leukemic cells.  Cancer Immunology Immunotherapy 19: 231-236, 1985.


5.      Beksaç M., Peterson C. and Reizenstein P.: Decreased  retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients. Cancer Chemotherapy and Pharmacology 15. 72-75, 1985.


6.      Reizenstein P., Beksaç M., Biberfeld P., Christensson B.,  Lagerlöf B., Lauren L., Öst A. and Porwit Ksiazek A. Leukemic myeloblasts expressing lymphoid markers. Acta Hematologica 74: 148-150, 1985.


7.      Hast R., Beksaç M., Axdorf S., Sjögren A.M., Öst A. and Reizenstein P.: Effect of retinoids on in vitro differentiation of bone marrow cells in the myelodysplastic syndrome. Medical Oncology and Tumor Pharmacotherapy 3: 35-38, 1986.


8.      Ösby E., Beksaç M., and Reizenstein P.: Alternating  combination therapy does not delay development of  refractoriness in myeloma. Anticancer Research 6:1145-1148, 1986.


9.      Beksaç M, Kansu E, Kars A, İbrahimoğlu Z, Fırat D: A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumour Pharmacother.5:253-257 , 1988


10.    Beksaç M., Akan H., Koç H., İlhan O., Ertürk P., Güneyli  A., İkizünal Y., Şardaş O.S.: P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing  protocols. Medical Oncology and Tumor Pharmacotherapy 9 (2); 101-105, 1992.


11.    Karakaya A., Tuncel N., Yücesoy B., Akın M., Çuhruk H., Şardaş O.S., Beksaç M.: The effects of volatile anesthetic agents on human immune system function via occupational  exposure. Immunopharm. Immunotoxicol 14 (182): 251-259, 1992.


12.    Beksaç M., Dalva K., Gönenç F., Dalva I., Gariboğlu S., Batur N., Çetin S.: Soluble CD23 and Interleukin 2 receptor levels in renal allograft recipients. Transplantation  Proceedings 25(2) (April) : 3043-3045, 1993.


13.    Beksaç M., Ertürk Ş., Akan H., Koç H., İlhan O.: The  clinical correlations of serum tumor necrosis factor alpha  in acute leukemias. A predictor of response and relapse?  Leukemia 7(11): 1773-1776, 1993.


14.    Akan H.,Koç H.,Beksaç M.,İlhan O.,Gürman G.,Aydoğdu İ.,Şardaş O.S.:Case report : complications of bone marrow transplantation ; a long way to run .Libri Oncol. 22(3) : 219-221 ,1993.


15.    Akan H.,Beksaç M.,Aydoğdu İ.,Koç H.,İlhan O.,Özcan M.:Perıpheral T cell receptors a,b and g,d ın Hodgkın's Lymphoma. Br. J.Haematol.87:544-547, 1994


16.    İlhan O, Uysal A, Aydoğdu İ, Beksaç M, Akan H, Koç H: Mitoxantrone and cytosine arabinoside in previously untreated patients with acute non-lymphocytic leukemia. Haematologica 27(2):93-97, 1996


17.    Arslan Ö, Akan H, Koç H, Beksaç M, İlhan O, Özcan M, Yalçın S, Gürman G, Konuk N, Uysal A Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen. Bone Marrow Transplantation 18:261-264, 1996



18.    İlhan O, Koç H, Akan H, Gürman G, Arslan Ö, Özcan M, Arıkan N, Sencer H, Konuk N, Uysal A, Beksaç M. Hemorragic cystitis as a complication of bone marrow transplantation. J of Chemotherapy 9:56-61, 1996


19.    Akan H, Koç H, Arslan Ö, Beksaç M, İlhan O, Gürman G, Özcan M. Febrile neutropenia in a bone marrow transplantation center. Int J of Antimicrob Agents 8:127-130 1997


20.    İlhan O, Akan H, Koç H, Gürman G, Arslan Ö, Özcan M, Erdi H, Erdem C, Konuk N, Uysal A, Beksaç M .Incidence of graft versus host disease in allogeneic bone marrow transplantation in a single center study from Turkey. Hematol Cell Ther 39:133-36, 1997


21.    Beksaç M, Beksaç MS, Tipi VB, Duru HA, Karakaş MÜ, Çakar AN. An artificial intelligent diagnostic sysytem on differential recognition of hematopoietic cells from microscopic images. Cytometry (Communications in clinical cytometry) 30:145-150, 1997.


22.    Üstün C, Koç H, Karayalçın S, Akyol G, Gürman G, İlhan O, Akan H, Özcan M, Arslan Ö, Konuk N, Uysal A, Beksaç M. Hepatitis B virus infection in allogeneic bone marow transplantation.  Bone Marrow Transplant 20, 289-196, 1997


23.    Koç H, Arslan Ö, Gürman G, Akan H, Özcan M, İlhan O, Aydoğdu İ, Arat M, Beksaç M, Konuk N, Uysal A. The use of high dose chemotherapy plus granulocyte colony stimulating factor for the salvage of refractory ort resistant relapse malignant lymphoma patients without stem cell support. Acta Haematol 98(3):136-139 1997


24.    Koç H, Gürman G, Arslan Ö, Özcan M, Akan H, İlhan O, Konuk N, Beksaç M, Uysal A. Allogeneic peripheral blood stem cell transplantation.  Is there an increased risk of GVHD in leukemia patients. J of Chemother 9(5):371-376 1997


25.    İlhan O, Beksac M, Arslan Ö, Özcan M, Koç H, Akan H. HLA DR2 a predictive marker in response to cyclosporine therapy in aplastic anemia. Int J Hematol 66:291-295, 1997


26.    Üstün C, Karavelioğlu D, İlhan O, Aydıntuğ O, Beksaç M . A case report of a patient who has pure red cell aplasia and rheumatoid arthritis Int J Hematol  66:505-512, 1997.


27.    Arslan Ö, Gürman G, Dilek İ, Özcan M, Koç H, İlhan O, Akan H, Konuk N, Uysal A, Beksaç M. Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey and review of the literature. Hematologia .29(2):133-7,1998.


28.    Dilek İ, Koç H, Demirer T, Anadolu R, Üstün C, Beksaç M, Erdi H, Özcan M, Akan H. Acquired icthyosis (superimposed upon chronic graft-versus-host disease) following an allogeneic peripheral blood stem cell transplantion in a patient wİth chronic myelogenous leukemia  “a case report” Bone Marrow Transplant .21(11):1159-61,1998


29.    Beksaç M,Arslan Ö, Koç H, Akan H, İlhan O, Arat M, Özcan M, Gürman G, Konuk N, Uysal. Randomized unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia. Medical Oncol .15:183 -190, 1998


30.    Arslan Ö, Üstün C, Arat M, Çelebi H, Akan H, Beksaç M, İlhan O, Gürman G, Özcan M, Konuk N, Uysal A, Koç H. .Allogeneic peripheral blood stem cell transplantation in acute nonlymphoblastic leukemia.Hematol.Oncol. 16(4):155-62,1998.


31.    Üstün C, Arslan Ö, Beksaç M, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O, Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek İ, Çelebi H, Coşkun HŞ. A retrospective comparison of allogeneic peripheral stem cell  and bone marrow transplantation .Results from a single center, a focus on the incidence of GVHD and relapse. Biol  Blood Marrow  Transplant. 5(1):28-35, 1999.


32.    Aydoğdu İ,İlhan O,Beksaç M, Koç H, Akan H, Konuk N, Uysal A..Serum erythropoetin levels in patients with leukemia on cytostatic treatment. Hematologia ( Budap) 29(2):133-7,1998


33.    Miniero R, Rocha V, Saracco P , Locatelli F , Brichard B, Nagler A, Roberts I, Yaniv I , Beksac M, Bernaudin F , Gluckman E on behalf of Eurocord.Cord blood transplantation in hemoglobinopathies. Bone Marrow Transpl 22 ( Suppl 1 ): S78-S79 , 1998



34.    Üstün C, İdilman R, Gürman G, Özcan M, Akyol G, Akan H,İlhan O,Beksaç M,Uysal A, Konuk N, Karayalcın S, Poyraz A, Van Thiel D, Koç H..Hematopoietic stem cell transplantation from non-replicative hepatitisB virus carriers is safe.J Hepatol.31:202-209,1999.


35.    Üstün C,Özcan M,Gürman G,Çakır M, Erekul S,Akyol G,Arat M,ÇelebiH, İdilman R,Akan H, İlhan O,Beksaç M,Koç H.Differences in liver pathology and clinical outcome between two patients with hepatitis B virus and graft versus host disease. Pathol Oncol Res. 5(3): 229-32,1999.


36.    Nergizoğlu G, Keven K, Ateş K, Üstün C, Tolunay Ö, Beksaç M, Karatan O, Ertuğ AE.Chronic graft versus host disease complicated by membranous glomerulonephritis. Nephrol Dial Transplant 14(10):2461-3,1999.


37.    İlhan O, Arslan Ö, Arat M, Beksaç M, Akan H, Özcan M, Gürman G, Konuk N, Uysal A, Koç H.The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfus Sci. 20(1):69-71,1999.


38.    Beksaç M, Arat M, Akan H, İlhan O, Koç H,Özcan M. Circulating CD44 and ICAM-1 levels in patients  with low grade NHL and CLL responsive or nonresponsive to ınterferon-alpha.Cancer 89(7):1474-1481,2000.


39.    Arslan Ö, Akan H, Arat M, Dalva K, Özcan M, Gürman G, İlhan O, Konuk N, Beksaç M, Uysal A, Koç H. Soluble adhesion molecules (s ICAM-1, l-selectin, e-selectin, sCD44 ) in healthy alogeneic peripheral stem cell donors primed with recombinant G-CSF. Cytotherapy 2(4): 259-265,2000.


40.    Arslan Ö, Coşkun HS, Arat M, Çelebi H, Özcan M, Gürman G, Üstün C, Demirer T, Akan H, İlhan O, Konuk N, Beksaç M, Uysal A, Koç H. Allogeneic peripheral blood stem cell transplantation for standard risk leukemias: Four years experience of Ibni Sina Hospital .Bone Marrow Transplant 25: 1229-1232, 2000


41.    Akan H, Güven N, Aydoğdu I, Arat M, Beksaç M, Dalva K.  Thrombopoietic cytokines in patients with ıron deficiency anemia with or without thrombocytosis.  Acta Haematol 103: 152-156, 2000.


42.    Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M, Parker K, Beksac M, Belson D, Moss JJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR. Human herpes virus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi’s sarcoma or primary effusion lymphoma. Clin Cancer Res. 6(11): 4226-33,2000.


43.    Beksaç M, Ma M, Akyerli C,Der Danielian M, Zhang L, Liu J, Arat M, Konuk N,Koc H, Özçelik T,Vescio H, Berenson JR. Frequent demonstration of Human herpes Virus 8 in bone marrow biopsy samples from Turkish patients with multiple myeloma. Leukemia ;15(8):1268-73. 2001


44.    Sonneveld P, S.Suciu, Weijermans P, Beksaç M, Neuwirtova R, Solbu , Lokhorst H, van der Lelie, Dohner H, Gerhatrz H, Segeren CM, Willemze R, Löwenberg B. Cyclosporin A combined with vincristine,doxorubicin, and dexamethasone(VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study( 06914).Br J Haem. 115: 895-902,2001.


45.    G.Ongun, Halıcı U, Leblebicioğlu K, Atalay V, Beksac M, Beksac S. Automated colour detection in blood cell images by an efficient snake algorithm.       Nonlinear analysis: Series B-Applications. 47: 5839-5847,2001.


46.    Gurman G, Dilek I, Arslan O, Arat M, Beksac M, Ilhan O, Ozcan M, Akan H, Dalva K, Konuk N, Uysal A, Koç H.The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation.  Transfus Apheresis Sci. 2001 Feb;24(1):23-8.


47.    Arat M, Arslan O, Beksaç M, Keven K, Nergizoglu G, Erturk S. Hematopoietic cell transplantation-related nephropathy (letter).Am J Kidney Dis.      38(1):218-9,2001.


48.    Ozcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, Ilhan O, Beksaç M, Gurman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koc H. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 27(5):499-505, 2001.


49.    Gurman G, Celebi H, Ustun C, Arat M, İlhan O, Ozcan M, Arslan O, Uysal A, Akan H, Beksac M, Konuk N, Koc H. Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia. Ther Apher. Feb;5(1):54-7, 2001.


50.    Ustun C; Beksac M; Dalva K; Koc H; Konuk N; Ilhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M .In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia Med Oncol 19( 1): 59-67 . 2002.


51.    Schmitz N, Beksac M., Hasenclever D.,Bacigalupo A., Ruutu T., Nagler A., Gluckman E.,Russell N.,Apperley J.F., Gorin N.C.,Szer J.,Bradstock K.,Buzyn A.,Clark P.,Borkett K.Gratwohl A. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 100(3):761-767,2002.


52.    Beksac M. et al. The role of pretransplant Interferon –alpha treatment on the outcome of stem cell transplantation from related donors in chronic myelogenous leukemia. Bone Marrow Transpl 31 (10): 897-904 ,2003.


53.    Kutlay S, Beksac M, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia.  Leukemia Lymphoma 44 (5): 791-795, 2003 .


54.    Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation.  Bone Marrow Transpl 32 (9): 873-880 Nov 2003 .


55.    Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 102 (8): 3043-3051, Oct 2003.


56.    Sanli H, Ekmekci P, Kusak F, et al. Hyperkeratosis of the nipple associated with chronic graft versus host disease after allogeneic haematopoietic cell transplantation . Acta Derm-Venereol 83 (5): 385-386 , 2003.


57.    Kuzu I, Beksac  M, Arat M,   Celebi  C, Elhan A,  Erekul S. Bone Marrow Microvessel Density (MVD) In adult Acute Myeloid Leukemia (AML): Therapy induced changes and effects on survival.  Leukemia Lymphoma , 44(5): 791-795,   2004.


58.    Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gurman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apheresis Sci. 30(3):185-7, 2004.


59.    İdilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat. 11(2):141-7, 2004.


60.    Akyerli C, Beksaç M, Holkoc M, Frevelc M, Dalva K, Özbek U, Soydan E, Özcan M, Özet G, İlhan O, Gürman G,  Akan H, Williams B, Özçelik T.  Expression of IFITM1 in Chronic Myeloid Leukemia  patients.  Leuk Res 29(3):283-286,2005.


61.    Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A,  Gluckman E, Russell N, Apperley J, Szerm J, Bradstock K, Buzyn A, Schlegelberger B, Matcham J, Gratwohl A. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica. ;90(5):643-8,2005.


62.    Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.Leukemia. 2005 Nov;19(11):1929-33.


63.    Bakanay SM, Dalva K, Arat M, Arslan O, Ayyildiz E, Beksac M, Ilhan O. Does continuous flow apheresis influence viability in allogeneic hematopoietic stem cell harvest? Transf. Apher.Sci. 2006 Apr;34(2):171-8. Epub 2006 Mar 20.


64.    Idilman R, Kuzu I, Erden E, Arat M, Soydan E, Soykan I, Akyol G, Karayalcin S, Akan H, Beksac M Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation. Bone Marrow Transplant. 2006 Jan;37(2):199-206.


65.    B G M Durie, J-L Harousseau, J S Miguel, J Bladé, B Barlogie, K Anderson, M Gertz, M Dimopoulos, J Westin, P Sonneveld, H Ludwig, G Gahrton, M Beksac, J Crowley, A Belch, M Boccadaro, I Turesson, D Joshua, D Vesole, R Kyle, R Alexanian, G Tricot, M Attal, G Merlini, R Powles, P Richardson, K Shimizu, P Tosi, G Morgan and S V Rajkumar on behalf of the International Myeloma Working Group.International uniform response criteria for multiple myeloma. Leukemia.2006 ,20(9):1467-73. Epub 2006 Jul 20.


66.    Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006 Dec;91(12):1722-3.


67.    Ali R.;Beksac M.;Ozkalemkas F.;Ozkocaman V.;Ozkan;Ozcelik;Tunali A. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymph 2007; 48(7):1426-8.


68.    Ludwig H, Durie B.G.M., Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Crowley J, Sonneveld P. Favorable prognostic features of young patients with multiple myeloma account for longer survival after conventional or high-dose therapy. Blood  2008 Apr 15;111(8):4039-47. Epub 2008 Feb 11.


69.    Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K,Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK,Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E,Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008 Mar;93(3):431-438.


70.    Beksaç M., Delforge M.,Richardson P.The evolving treatment paradigm of multiple myeloma: From past to present and future.( Sürekli gelişmekte olan bir tedavi yaklaşımı: Multipl miyeloma tedavisinin geçmişi, bugünü ve geleceği ) Turk J Hematol 2008 ;25(2): 60-



71.    Ozet A., Guran S., Beksaç M. Familial multiple myeloma associated with chronic inflammation: First report from Turkey. Clin Lymph Myeloma.2008;8(4):246-8.


72.    Sanli H, Akay BN, Arat M, Koçyigit P, Akan H, Beksac M, Ilhan O.Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. Dermatology. 2008;216(4):349-54.


73.    Brand A, Rebulla P, Engelfriet CP, Reesink HW, Beguin Y, Baudoux E, Kögler G, Ebrahimi M, Grazzini G, Costa AN, Bosi A, Sacchi N, Lombardini L, Pupella S, Lecchi L, Garcidueñas ED, van Beckhoven JM, de Wit HJ, Fibbe WE, Zhiburt EB, Bart T, Beksaç M, Navarrete C, Regan F. International forum: cord blood banking. Vox      Sanguinis 2008; 95(4):335-48.


74.    Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of Multiple Myeloma. Leukemia. 2009 ;23(9):1545-56.



75.    Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A,Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, arlogie B,Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M,Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W,Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group.Collaborators: Alexanian R, Anderson K, Attal M, Avet-Loiseau H, Badros A,Bergsagel L, Blade J, Barlogie B, Batille R, Beksac M, Belch A, Bensinger B,Boccadoro M, Cavo M, Chen WM, Child T, Chim J, Comenzo R, Crowley J, Dalton W,Davies F, de Souza C, Delforge M, Dimipoulous M, Dispenzieri A, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, Gertz M, Gibson J, Goldschmidt H,Greipp P, Hajek R, Hardan I, Harousseau JL, Hata H, Hattori Y, Ho J, Hungria V,Hussein M, Ida S, Jacobs P, Jagannath S, Jian H, Joshua D, Kawano M, Kumar S,Kyle R, Lahuerta J, Lee JH, Lokhorst H, Ludwig H, LeLeu X, Maiolino A, Mehta J,Merlini G, Moreau P, Morgan G, Munshi N, Palumbo A, Pavlovsky S, Niesvizky R,Novis Y, Nouel A, Powles R, Pilarski L, Rajkumar SV, Reece D, Reiman T,Richardson P, Rodriquez A, Sezer O, Shaughnessy J, Shimizu K, Siegel D, Tricot G,San Miguel J, Singhal S, Sonneveld P, Shustik C, Spencer A, Stewart K, Tosi P,Turesson I, Van Ness B, Van Riet I, Vescio R, Vesole D, Waage A, Wang M, Weber D,Westin J, Wheatley K, Yehuda DB, Zonder J. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23(2):215-24.


76.    Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M,

Schmidt A, Yang E, van Walraven AM. Donor safety: the role of the WMDA in

ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant. 2010 ;45(5):832-8.



77.    Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Beksac M, Hasenclever D, Socie, G, Schmitz N. Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomized trial.

Lancet Oncol. 2010;11(4):331-8. 


78.    Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M,Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N,Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, ShpilbergO, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist.2010;15(1):6-25. 


79.    Beksac M, Rıdvan A, Ozcelik T, Ozcan M, Ozcebe O, Bayık M, Paydas S, Buyukasık Y, İlhan O, Ozkalemkas F, Gurman G, Uysal A, Akan H, Akcaglayan Soydan E, Tunalı A. Short and long term effects of  granulocyte colony stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. Leuk Res 2011;35(3):340-5.


80.    Beksac M, Haznedar R, Tuglular T, Ozdogu H, İ.Aydogdu, N.Konuk, G.Aysucak, I.Kaygusuz, S.Karakus, E.Kaya, R.Ali, Z.Gulbas, G.Ozet, H.Goker, L.Undar. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur. J. Hematol.  2011 ;86(1):16-22.


81.    Attar A, Ayten M, Özdemir M, Özgencil E, Bozkurt M, Kaptanoğlu E, Beksac M, Kanpolat Y. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy 2011;13(1):54-



82.    Topcuoglu P, Arat M, Ozcan M, Arslan O, Ilhan O, Beksac M, Gurman G.

Ann Hematol. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. Ann Hematol. 2011 ;5. [Epub ahead of print]


83.    Abi-Rached L, Jobin MJ, Kulkarni S, McWhinnie A, Dalva K, Gragert L, Babrzadeh F,

Gharizadeh B, Luo M, Plummer FA, Kimani J, Carrington M, Middleton D, Rajalingam

R, Beksac M, Marsh SG, Maiers M, Guethlein LA, Tavoularis S, Little AM, Green RE,

Norman PJ, Parham P .The shaping of modern human immune systems by multiregional admixture with archaic humans. Science . 2011 7;334(6052):89-94.


84.   Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L,

Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C,

Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A,

Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011 ;12 . [Epub ahead of print]


85 .   Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J,

Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel

D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer

O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group;

International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina

M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille

R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé

J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ,

Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M,

Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand

JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt

S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H,

Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H,

Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M,

Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H,

Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G,

Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel

A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N,

Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L,

Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D,

Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P,

Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken

K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J.

Risk of progression and survival in multiple myeloma relapsing after therapy with

IMiDs and bortezomib: A multicenter international myeloma working group study.

Leukemia. 2011; 29. doi: 10.1038/leu.2011.196.



86.    Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F,

Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T,

Morris C, Niederwieser D, Gahrton G.  Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011 1;29(22):3016-22.



87.    Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary

JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I,

Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011 4;118(5):1239-47.


88.   Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach

J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da

Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J,

Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist. 2011;16(4):388-403.



89.    Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H,

Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P . Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25(5):749-60.



90.   Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A,

Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC,

Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC,

Jagannath S. Consensus recommendations for standard investigative workup: report of the

International Myeloma Workshop Consensus Panel 3. Blood. 2011 5;117(18):4701-5.


91. Beksac M, Preffer F. Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? Bone Marrow Transplant. 47(11):1391-6. doi: 10.1038/bmt.2011.240. Epub 2011 Dec 5,


92. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi

N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo

M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R,

Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos

M, Lonial S, Jagannath S, Blad© J, Miguel JS, Morgan G, Anderson KC, Durie BG,

Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2011 ;26(4):595-608.


93. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G,

Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV,

Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H,

Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119(13):3003-15.


94. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H,

Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M,

Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda

D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015

Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

N Engl J Med. 2012 ;366(19):1759-69.


95.Bakanay SM, Serbest E, Dalva K, Kuzu I, Beksac M. Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?Case Report Med. 2012;2012:319530.


96. Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X,

Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M,

Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M,

Lokhorst H, Boccadoro M, Rodon P, Sonneveld P. Safety of thalidomide in newly diagnosed elderly myeloma patients: an individual patient data meta-analysis of six randomized trials.

Haematologica. 2013 Jan;98(1):87-94.


97.Beksaç M, Dalva K. Role of killer immunoglobulin-like receptor and ligand

matching in donor selection. Bone Marrow Res. 2012;2012:271695.



98.Ozdemir M, Attar A, Kuzu I, Ayten M, Ozgencil E, Bozkurt M, Dalva K, Uckan D,

Kılıç E, Sancak T, Kanpolat Y, Beksac M. Stem cell therapy in spinal cord injury:

in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. Stem Cell Rev. 2012 Sep;8(3):953-62.


100. Gupta V, Richards S, Rowe J; Acute Leukemia Stem Cell Transplantation Trialists'

Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first

remission: an individual patient data meta-analysis. Blood. 2013 Jan 10;121(2):339-50.


101.Anghel R, Bachmann A, Bekşac M, Brodowicz T, Finek J, Komadina R,

Krzemieniecki K, Lang I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T,

Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive

agents in the prevention of skeletal-related events in metastatic bone disease.

Wien Klin Wochenschr. 2013 Aug;125(15-16):439-47.


 102.Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E,

Couturier C, Mazier MA, Angermund R, Facon T. Phase II study of

bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for

sub-optimal response as second-line treatment for patients with multiple myeloma.

Haematologica. 2013 Aug;98(8):1264-72.



103. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin

L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S,

Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D,

Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell

Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell

transplantation vs autologous transplantation in multiple myeloma: long-term

results of the EBMT-NMAM2000 study. Blood. 2013 Jun 20;121(25):5055-63.






104. Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik

M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag

DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X,

Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW,

Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P,

Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-Dose Cytarabine in

Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46

Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. J

Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013

Dec 2. PubMed PMID: 24297940.



105. Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos MV, Gimsing P, Mazzone

C, Gottardi D, Omedè P, Zweegman S, Lahuerta JJ, Zambello R, Musto P, Magarotto

V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel AI,

Liberati AM, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A,

Miguel JS, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Bortezomib,

Melphalan, Prednisone (VMP) versus Melphalan, Prednisone, Thalidomide (MPT) in

elderly newly diagnosed Multiple Myeloma patients: A retrospective case-matched

study. Am J Hematol. 2013 Nov 25. doi: 10.1002/ajh.23641. [Epub ahead of print]

PubMed PMID: 24273190.



106. Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Diaz AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MM, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani S, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 Mar 8. 91(6): 575–580 doi: 10.1002/ajh.24351. [Epub ahead of print]




107. Beksac M, Yurdakul P.Front Med (Lausanne). 2016 Feb 17;3:7. doi: 10.3389/fmed.2016.00007. eCollection 2016. Review. How to Improve Cord Blood Engraftment? PMID:26925402

108. Beksac M.Front Med (Lausanne). 2016 Jan 11;2:95. doi: 10.3389/fmed.2015.00095. eCollection 2015. Review. Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants? PMID:26793711

109. Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116

110. Hidayat AN, Aki-Yalcin E, Beksac M, Tian E, Usmani SZ, Ertan-Bolelli T, Yalcin Insight into human protease activated receptor-1 as anticancer target by molecular modelling. I.SAR QSAR Environ Res. 2015;26(10):795-807. doi: 10.1080/1062936X.2015.1095799. Epub 2015 Oct 26.PMID:26501801

111. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network guidelines for the management of multiple myeloma-related complications.European Myeloma Network.Haematologica. 2015 Oct;100(10):1254-66. doi: 10.3324/haematol.2014.117176.PMID: 26432383

112. Kalafat E, Yuce T, Konuralp B, Katlan DC, Kalaylioglu Z, Beksac M, Koc A, Soylemez F. Effects of in utero cord blood collection on post-cesarean hemoglobin levels.Eur J Obstet Gynecol Reprod Biol. 2015 Oct;193:123-6. doi: 10.1016/j.ejogrb.2015.07.022. Epub 2015 Aug 6.PMID:26295789

113. Beksac K, Beksac M, Dalva K, Karaagaoglu E, Tirnaksiz MB Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. PLoS One. 2015 Jul 16;10(7):e0132526. doi: 10.1371/journal.pone.0132526. eCollection 2015.PMID: 26181663

114. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: Expert Rev Anticancer Ther. 2015;15(9):1121. PMID:26051506


115. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.PMID:26035255

116. Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A. Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. Acta Haematol. 2015;133(4):372-80. doi: 10.1159/000370023. Epub 2015 Mar 24.PMID: 2582429

117. Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.PMID:25621805

118. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.PMID: 25439696

119. Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015 Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22.PMID:25402977

120. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-1206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. PMID:25242045

121. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE; World Marrow Donor Association Clinical Working Group Committee. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant. 2014 Jul;49(7):880-6. doi: 10.1038/bmt.2014.67. Epub 2014 Apr 7.PMID:24710563

122. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.PMID:24497560

123. Paul G. Richardson,Image1 Vânia T. M. Hungria,2 Sung-Soo Yoon,3 Meral Beksac,4 Meletios Athanasios Dimopoulos,5Ashraf Elghandour,6 Wieslaw W. Jedrzejczak,7 Andreas Guenther,8 Thanyaphong Na Nakorn,9 Noppadol Siritanaratkul,10 Robert L. Schlossman,1 Jian Hou,11 Philippe Moreau,12 Sagar Lonial,13 Jae Hoon Lee,14 Hermann Einsele,15 Monika Sopala,16 Bourras-Rezki Bengoudifa,16 Claudia Corrado,16 Florence Binlich,17 and Jesús F. San-Miguel18 “Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment” Received 2015 Sep 8; Accepted Blood. 2016 Feb 11; 127(6): 713–721. Prepublished online 2015 Dec 2. doi: 10.1182/blood-2015-09-665018


124. Antonio Palumbo, M.D., Asher Chanan‑Khan, M.D., Katja Weisel, M.D., Ajay K. Nooka, M.D., Tamas Masszi, M.D., Meral Beksac, M.D., Ivan Spicka, M.D., Vania Hungria, M.D., Markus Munder, M.D., Maria V. Mateos, M.D., Tomer M. Mark, M.D., Ming Qi, M.D., Jordan Schecter, M.D., Himal Amin, B.S., Xiang Qin, M.S., William Deraedt, Ph.D., Tahamtan Ahmadi, M.D., Andrew Spencer, M.D., and Pieter Sonneveld, M.D., for the CASTOR Investigators “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma”

N Engl J Med 2016;375:754-66. DOI: 10.1056/NEJMoa1606038


125. Beksac M. Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?". Front Med (Lausanne). 2016 May 13;3:20. doi:10.3389/fmed.2016.00020. eCollection 17 şubat 2016. PubMed PMID: 27243013; PubMed Central PMCID: PMC4865490. 10.3389/fmed.2016.00007



126. Özen M, Üstün C, Öztürk B, Topçuoğlu P, Arat M, Gündüz M, Atilla E, Bolat G,Arslan Ö, Demirer T, Akan H, İlhan O, Beksaç M, Gürman G, Özcan M. “Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study”. Turk J Haematol. 2016 Apr 18. doi: 10.4274/tjh.2015.0346. [Epub ahead of print] PubMed PMID: 27094579.


127. Özdemir NZ, Şahin U, Merter M, Gündüz M, Ateşağaoğlu B, Beksaç M. “A Case of Superwarfarin Poisoning due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker”. Turk J Haematol. 2016 Sep 5;33(3):251-3. doi: 10.4274/tjh.2015.0433.PubMed PMID: 27093901.


128. Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P. “HLA polymorphism and risk of multiple myeloma”. Leukemia. 2016 Jul 27. doi: 10.1038/leu.2016.199. [Epub ahead of print]


129. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I,Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators..”Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma”. N Engl J Med. 2016 Aug 25;375(8):754-66.


130. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A,Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J,Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. “Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial”. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.


131. Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ,Nguyen TS, Cronier DM, Palumbo A. “Phase 2 study of tabalumab, a human anti-B-cellactivating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma”. Br J Haematol. 2016 Dec 22. doi:10.1111/bjh.14483. [Epub ahead of print] PubMed PMID: 28005265.


132. Gencer EB, Yurdakul P, Dalva K, Beksac M. “Flow Cytometric Aldehyde Dehydrogenase (ALDH) Assay Enables a Fast and Accurate Human Umblical Cord Blood  Hematopoietic Stem Cell Assessment. Turk J Haematol. 2016 Dec 12. doi:10.4274/tjh.2016.0214. [Epub ahead of print] PubMed PMID: 27956370.


133.  Sezer O, Beksac M, Hajek R, Sucak G, Cagırgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Tımuragaoglu A, Dechow T, Lang A, Tuglular T, Drach J, Olie RA, Terpos E, "Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: A randomized phase 2 study.", Br J Haem, 176(5) 783-795. March 2017



134.  Beksac M, Beksac S, Yucesoy M, Orgul G, Portakal O, "The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females", Clinical and Experimental Health Sciences 2017-06-19


135. Ilhan O,Arat M, Arslan O, Ayyıldız E, Sanlı H, Beksac M, Ozcan M, Gurman G, Akan H, "Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease", Transfusion Apheresis, 2004 Jun;30(3):185-7.


136. Gündüz M, Ozen M, Şahin U, Toprak S.K, Bozdag S.C, Yüksel M, Arslan O, Ozcan M, Demirer T, Beksac M, Ilhan O, Gürman G, Topçuoğlu P, "Subsequent Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation", Clin Transplant 2017.


137.  Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayet AN, Beksac M, Aki-Yalçın E, “Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells.” Anticancer Agents Med. Chem., December 2017,


138.   Dimopoulus MA, Lonial S, White D, Moreau P, Palumbo A, San- Miguel  J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P, “Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.” Br J Haem, 178(6):896-905, September 2017


139.  San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG, “Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.” Br J Haematol.179(1):66-74, October 2017


140.  Kumar SK, Dimopoulos MA,  Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M,  Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM, “Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.”Leukemia, 31(11):2443-2448, Novenber 2017


141. Atilla E, Atilla PA, Bozdag SC, Yüksel MK, Toprak SK, Topcuoglu P, Akay BN, Sanlı H, Akan H, Demirer T, Beksac M, Arslan O, Ozcan M, Gurman G, Ilhan O, “Extracorporeal photochemotherapy in mycosis fungoides.” Transfus Clin Biol. 24(4):454-457, Novenber 2017


142. Gencer EB, Yurdakul P, Dalva K, Beksac M, “Flow Cytometric Aldehyde  Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment.” Turk J Haematol. 1;34(4):314-320, Decenber 2017


143. Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayat AN, Beksac M, Aki-Yalcin E,Yalcin I, Sunguroglu A. “Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells”. Anticancer Agents Med Chem. 2017 Dec 29. doi: 10.2174/1871520618666171229222534. [Epub ahead of print] PubMed PMID: 29298654.


144. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. “ Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel”. Journal of Hematology & Oncology. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1.


145. Sahin U, Dalva K, Gungor F, Ustun C, Beksac M. “Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation”. Ann Hematol.  16 March 2018 97(6):1027-1039. doi: 10.1007/s00277-018-3274-0. Epub 2018 Mar 16.


146. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. “ Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.” Leukemia. 2018 May 2, 32(7):1542-1560, doi: 10.1038/s41375-018-0040-1


147. Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A  “Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiplemyeloma”.Leuk Lymphoma. ISSN: 1029-2403 2018 May 9 60:1, 163-171, DOI: 10.1080/10428194.2018.1459609


148. Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A, “A Comparison of the Efficacy of Immunomodulatory-free Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis” Clinical Lymphoma Myeloma and Leukemia, ISSN: 1029-2403 Volume 18, Issue 3, 08 Nov 2018, Pages 163-173.e6 doi: 10.1016/j.clml.2017.12.011


149. Orgul G, Yucesoy HM, Portakal O, Beksac M, Beksac MS, “The Impact of 17B Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females” Clınıcal And Experımental Health Scıences Volume:8 Issue:2 Pages:118-121 DOI: 10.5152/clinexphealthsci.2017.432 JUN 2018


150. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, M. Mark T, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, K. Nooka A, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M,  Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV, “Daratumumab Plus Bortezomib And Dexamethasone Versus Bortezomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of CASTOR” Haematologica 20 September 2018 haematol 2018. 103:12 2079-2087 194118; Doi:10.3324/haematol.2018.194118


151. Cengiz Seval G, Beksac M, “The safety of bortezomib for the treatment of multiple myeloma” Expert Opin Drug Saf. 2018 Sep 17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30.


152. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Soledad Duran M, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Peceliunas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Feys C, Thoret-Bauchet F, Boccadoro M, “Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study” Clınıcal Lymphoma Myeloma & Leukemıa  October  2018 V: 18 I: 10 P: E401-E419  DOI: 10.1016/j.clml.2018.06.018


153. Atilla E, Yalciner M, Atilla PA, Ates C, Bozdag SC, Yuksel MK, Toprak SK, Gunduz M, Ozen M, Akan H, Demirer T, Arslan O, Ilhan O, Beksac M, Ozcan M, Gurman G,  Topcuoglu P, “Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?” International medical press, July 2018 doi: 2018;23(8):647-653. doi: 10.3851/IMP3252.


154. Tanaçan A, Yurdakul P, Aktoz F, Örgül G, Beksaç M, Beksaç MS, “Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience” Turkish Journal of Medical Sciences, 2018 Oct 31;48(5):961-966 doi: 10.3906/sag-1802-54.


155. Arslan O, Elcin AE, Atilla E , Seker S, Baydin P , Gunduz M, Ozen M, Bayraktar UD, Ilhan O , Beksac M, Elcin YM, Gurman G, “Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies” Biology of Blood and Marrow Transplantation, March 2018 24(3), S178-S179 DOI:


156. Jurczyszyn A,Castillo J, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, Hus I, Madry K, Gaida Wa, Usnarska Zl, Debski J, Atilla E, Beksaç M, Mele G, Sawicki W, Jayabalan D, Charlinski G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungaria V, Richardson P, Laubach J, Guerrero GT, Liu J, Vesole DH, “Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.” Leukemia & Lymphoma, 2018 Jul ISSN: 1029 2403 60:1 118-123 doi: 10.1080/10428194.2018.1473574.


157. Atilla E, Özel F, Ataca Atilla P, Topçuoğlu P, Akan H, Beksaç M, İlhan O, Özcan M, Arslan Ö, Gürman G, Toprak SK, “Kronik Lenfositik Lösemide Tanı Anında Hipogammaglobulinemi Sağkalım Ve Enfeksiyon Riski Üzerine Etkili midir?” Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 2018 Ekim 20:3 doi: 10.24938/kutfd.439565


158. Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayat AN, Beksac M, Aki-Yalcin E, Yalcin I, Sunguroglu A, “Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells” Anti-Cancer Agents in Medicinal Chemistry,  18(11):1521-1530 doi :10.2174/1871520618666171229222534


159. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P. “Prevention and management of adverse events  of Novel agents in multiple myeloma: A consensus of the european myeloma network”. Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review. PubMed PMID: 29251284.


160. Richardson, PG., Oriol, A., Beksac, M., Liberati, A.M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., Miguel, JS., Sunami, K., O’Gorman,  P., Sonneveld, P., Robak, P., Semochkin, S., Schey, S., Yu, X., Doerr, T., Bensmaine, A., Biyukov, T., Peluso, T., Zaki, M., Anderson, K., Dimopoulos, M., on behalf of the OPTIMISMM trial investigators (2019) “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.” Lancet Oncol.  Jun 2019;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4.


161.Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min C.K., Pluta, A., Chng, W.J., Kaiser, M., Zweegman, S., Mateos, M.V., Spencer, A., Iida, S., Morgan, G.,  Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A.B., Gupta, N., Labotka, R., Rajkumar, S.V., TOURMALINE-MM3 study group (2019) “Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial” Lancet. Jan 19 2019 393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4.


162.Weisel, K., Sonneveld, P., Spencer, A., Beksac, M., Rizzo, M., Xu, Y.X., Fahrbach, K., Gaudig, M., Slavcev, M., Dearden, L., Lam, A (2019), “A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis” LEUKEMIA & LYMPHOMA  JAN 2 2019, ISSN: 1029-2403 Volume: 60  Issue: 1  Pages: 151-162 DOI: 10.1080/10428194.2018.1466392


163. Jurczyszyn, A., Castillo, J.J., Avivi, I., Czepiel, J., Davila, J., Vij, R., Fiala, M.A., Gozzetti, A., Grzasko, N., Milunovic, V., Hus, I., Madry, K., Waszczuk-Gajda, A., Usnarska-Zubkiewicz, L., Debski, J., Atilla, E., Beksac, M., Mele, G., Sawicki, W., Jayabalan, D., Charlinski, G.,  Szabo, A.G.,  Hajek, R., Delforge, M., Kopacz, A., Fantl, D., Waage, A., Crusoe, E., Hungria, V., Richardson, P., Laubach, J., Guerrero-Garcia, T., Liu, J.E.Q., Vesole, D.H (2019) “Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients” LEUKEMIA &LYMPHOMA JAN 2 2019, ISSN; 1029-2403 Volume:60 Issue:1 Pages:118-123 DOI: 10.1080/10428194.2018.1473574 


164. Kumar, S., Durie, B., Nahi, H., Vij, R., Dimopoulos, M.A., Kastritis, E., Terpos, E., Leleu, X.,  Beksac, M., Goldschmidt, H., Hillengass, J., Su, Z., Hutton, B., Cameron, C., Khan, I., Lam, A (2019) “Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma” LEUKEMIA & LYMPHOMA JAN 2 2019 ISSN: 1029-2403 Volume: 60 Issue:1 Pages:163-71 DOI:10.1080/10428194.2018.1459609  


165. Seval, G.C., Ozkan, E., Beksac, M (2019). “PET with Fluorodeoxyglucose F 18/ Compu ted Tomog raphy as aS taging Tool in Mul tiple Myeloma” PET Clin. Jul;14(3):369-381. doi: 10.1016/j.cpet.2019.03.009. Epub


166. Seval, G.C., Beksac, M (2019) “A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma” Expert Opin Drug Saf. 2019 May 9:1-9. doi: 10.1080/14740338.2019.1615051


167. Beksac MS, Fadiloglu E, Cakar AN, Gurbuz RH, Atilla, Onbasilar I, Beksac K, Katlan DC, Mumusoglu S, Calis P, Beksac M, “Fetal Cell Microchimerism; Normal and Immunocompromised Gestations in Mice” Fetal and Pediatric Pathology, 22 Aug 2019, ISSN: 1551-3815 (Print) 1551-3823 (Online), DOI: 10.1080/15513815.2019.1651803ü


168. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Genneryl AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, de Latour RP, Snowden JA, Styczynski J, Yakoub-Agha I, Kroger N, Mohty M, Albert M, Alexander T, Averbuch D, Baron F, Bazarbachi E, Beksac M, Brissot E, Bug G, Cesaro S, Chalandon Y, Ciceri F, Czerw T, Dazzi F, Esteve J, Fleischhauer K, Garderet L, Giebel S, Gil L, Gilleece M, Gorin NC, Hayden P, Halter J, Boluda JCH, Hudecek M, Kleinschmidt K, Kenyon M, Koenecke C, Locatelli F, Malard F, McLornan D, Mikulska M, Murray J, Onida F, Pedrazzoli P, Penack O, Peric Z, Risitano A, Robin M, Robinson S, Ruggeri A, Sanz J, Savani B, Schetelig J, Schied C, Schmid C, Schoemans H, Schonland S, Sharrack B, Shouval R, Spyridonidis A, Toubert A, Tourniac O, Urbano-Ispizua A, Vago L, van Gelder M, Verhoeven B, Versluis J, Wietten L, Willasch A, “Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019” BONE MARROW TRANSPLANTATION, OCT 2019, Volume: 54 Issue: 10 Pages: 1525-1552, DOI: 10.1038/s41409-019-0516-2


169. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study”. The Lancet. 2019 Nov 14. doi: 10.1016/S0140-6736(19)32556-5.


170. Mateos M-V, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O’Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P, “Insights on Multiple Myeloma Treatment Strategies”. HemaSphere: February 2019 - Volume 3 - Issue 1 - p e163  doi: 10.1097/HS9.0000000000000163


171. Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA. “A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome”. Haematologica. 2019 Jul 5, 104:11 doi : 10.3324/haematol.2019.219295.


172. Atilla PA, Yalciner M, Atilla E, Idilman R, Beksac M, “Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib Containing Regimens” TURKISH JOURNAL OF HEMATOLOGY 2019 Volume: 36 Issue: 4 Pages: 266-273 DOI: 10.4274/tjh.galenos.2019.2019.0103


173. Sahin Ugur, Beksac M, “Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies” Clinical Hematology International Vol. 1(3), September 2019, pp. 134–141 DOI:


174. Beksac, M., Balli, S., Yildiz, D.A., “Drug Targeting of Genomic Instability in Multiple Myeloma” Frontıers in Genetıcs Volume:11, DOI: 10.3389/fgene.2020.00228   APR 9 2020


175. Beksac, M., Cengiz Seval, G., Kanellias, N., Coriu, D., Rosiñol, L., Ozet, G., Goranova-Marinova, V., Unal, A., Bila, J., Ozsan, H., Ivanaj, A., Balić, L.I., Kastritis, E., Bladé, J., Dimopoulos, M.A., “A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome”. Haematologica. JAN 1, 2020, Volume: 105 Issue: 1 Pages: 201-208 DOI: 10.3324/haematol.2019.219295


176. Landgren, O., Chari, A., Cohen, Y., Spencer, A., Voorhees, P., Estell, J., Sandhu, I., Jenner, M., Williams, C., Cavo, M., van de Donk, N., Beksac, M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P., Neff, T., Heuck, C., Qi, M., Hofmeister, C., “Daratumumab Monotherapy for Patients With Intermediate-risk or High-risk Smoldering Multiple Myeloma: A Randomized, Open-label, Multicenter, Phase 2 Study (CENTAURUS)” Leukemia, DOI: 10.1038/s41375-020-0718-z  Early Access: FEB 2020


177. Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M.T., Dimopoulos, M.A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., van der Velden, V.H.J.,  Zamagni, E., Palumbo, G., Patriarca, F., Montefusco, V., Galli, M., Maisnar, V., Gamberi, B., Hansson, M., Belotti, A., Pour, L., Ypma, P., Grasso, M., Croockewit, A., Ballanti, S., Offidani, M., Vincelli, I.D., Zambello, R., Liberati, A.M., Andersen, N.F., Broijl, A., Troia, R., Pascarella, A., Benevolo, G., Levin, M.D., Bos, G., Ludwig, H., Aquino, S., Morelli, A.M., Wu, K.L., Boersma, R., Hajek, R., Durian, M., Borne, P.A., Toritto, T.C., Driessen, C., Specchia, G., Waage, A., Gimsing, P., Mellqvist, U.H., Kooy, M.M., Minnema, M., Mandigers, C., Cafro, A.M., Palmas, A., Carvalho, S., Spencer, A., Boccadoro, E., Sonneveld, P.,  “Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study” Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30


178. Garderet, L., Morris, C., Beksac, M., Gahrton, G., Schonland, S., Yakoub-Agha, I., Hayden, P.J.,  “Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review From the Chronic Malignancies Working Party of the EBMT”  Biol Blood Marrow Transplant. 2020 May 14;S1083-8791(20)30222-6.   doi: 10.1016/j.bbmt.2020.04.016


179. Özkan, E., Araz, M., Seval, G.C., Nak, D., Beksaç, M., “A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT”  Turk J Haematol. 2020 Apr 24.  doi: 10.4274/tjh.galenos.2020.2020.0134.


180. Beksac, M., Aydin, Y., Goker, H., Turgut, M., Besisik, S.K., Cagirgan, S., Tuglular, T., Vural, F., Yagcı, M., Alacacıoglu, İ., Aytan, P., Goksoy, H.S., Gulbas, Z., Gunes, A.K., Gurkan, E., Hacıoglu, S.K., Karti, S.S., Kaynar, L., Ozdogu, H., Paydas, S., Solmaz, S., Sonmez, M., Tekgunduz, E., Yıldırım, R., Ilhan, O., “Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma” Clin Lymphoma Myeloma Leuk. 2020 AUG, S2152-2650(20)30114-2.  doi: 10.1016/j.clml.2020.02.017.


181.Chen, Y., Li, R., Zhu, Y., Zhong, S., Qian, J., Yang, D., Jurczyszyn, A., Beksac, M., Gu, C., Yang, Y., “Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma” Front Oncol. 2020; 10: 767. Published online 2020 May 15. doi: 10.3389/fonc.2020.00767


182. Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., Arriba, F., Mateos, M.V., West, S., Spencer, A., Rajkumar, S.V., Suryanarayan, K., Czorniak, M., Teng, M., Labotka, R., Dimopoulos, M.A., “Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)” Clinical Lymphoma Myeloma and Leukemia, 2020, Volume 19, Issue 10, Page e293,


183. Atilla, P.A., Akkus, E., Atilla, E., Gokmen, N., Bozdag, S.C., Yuksel, M.K., Toprak, S.K., Baskal, N., Akan, H., Demirer, T., Topcuoglu, P., Arslan, O., Ilhan, O., Ozcan, M., Beksac, M., Gurman, G., “Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation” CLINICAL TRANSPLANTATION, AUG 2020, Article Number: e14049        DOI:10.1111/ctr.14049


184. Ludwig, H., Boccadoro, M., Moreau, P., San-Miguel, J., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T., Driessen, C., Hajek, R., Dimopoulos, M.A., Gay, F., Avet-Loiseau, H., Terpos, E., Zojer, N., Mohty, M., Mateos, M.V., Einsele, H., Delforge, M., Caers, J., Weisel, K., Jackson, G., Garderet, L., Engelhardt, M., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., Abildgaard, N., Bringhen, S., Sonneveld, P., “Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network” LEUKEMIA     AUG 2020      DOI: 10.1038/s41375-020-01016-0


185. Beksac, M., Kroger, N., Byrne, J.L., Ganser, A., Yegin, Z.A., Schonland, S., “Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)” Bone Marrow Transplantation, 2 AUG 2020  DOI: 10.1038/s41409-020-01010-1


186. Atilla, P.A., Akkus, E., Atilla, E., Gokmen, N., Bozdag, S.C., Toprak, S.K., Yuksel, M.K., Ozcan, M., Demirer, T., Ilhan, O., Beksac, M., Akan, H., Arslan, O., Topcuoglu, P., Gurman, G., “Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation” TRANSFUSION CLINIQUE ET BIOLOGIQUE, AUG 2020 Volume: 27 Issue: 3 Pages: 115-121 DOI:10.1016/j.tracli.2020.06.008


187. Beksac, M., Savani, B.N., “Prognostic scoring system after transplantation in myeloma: predicting early relapse” BRITISH JOURNAL OF HAEMATOLOGY, JUL 2020,  DOI: 10.1111/bjh.16986


188. Kaiser, M., Beksac, M., Gulbrandsen, N., Schjesvold, F., Hajek, R., Moreau, P., de la Fuente, F.D., Mateos, M.V., West, S., Spencer, A., Rajkumar, S.V., Suryanarayan, K., Czorniak, M., Li, C., Teng, Z.Y., Labotka, R., Dimopoulos, M.A., “Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma” ANNALS OF HEMATOLOGY, AUG 2020, Volume: 99 Issue: 8 Pages: 1793-1804 DOI: 10.1007/s00277-020-04149-5


189. Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T.M., Spicka, I., Masszi, T., Lauri, B., Levin, M.D., Bosi, A., Hungria, V.,  Cavo, M., Lee, J.J., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., Min, C.K., Chanan-Khan, A.A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J.C., Shin, H.J., Sonneveld, P., Casneuf, T., DeAngelis, T., Amin, H., Ukropec, J., Kobos, R., Mateos, M.V.,  “Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk” Journal of Hematology & Oncology,  2020 Aug 20;13(1):115. doi: 10.1186/s13045-020-00948-5.